CTi Biopharma — Cell Therapeutics — Investor Presentation (September 2012)
37 slides from CTi Biopharma's investor presentation, Sep 10, 2012
Slide 1: Cell Therapeutics, Inc. Company Overview
MPN Pacritinib Phase 3* MDS/AML Tosedostat Phase 3* NHL Pixuvri™ Marketed (EU) Cell Therapeutics, Inc. Company Overview * Phase 3 ready. Covering a Spectrum of Blood Related Cancers Exhibit 99.1
Slide 2: Forward Looking Statement
Forward Looking Statement This presentation includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results and the market price of CTI's securities. Specifically, the risks and uncertainties th
Slide 3: Company Overview
Company Overview Hematology/Oncology-focused biotechnology company 1 commercial product • Pixuvri ™ : for the treatment of non-Hodgkin's lymphoma (“NHL”) - Conditional Marketing Authorization May 2012- E.U. launch September - Attractive “niche” market ~16,000 patients (1) ; 10 yrs market exclusivity
Slide 4: Current Pipeline
Current Pipeline Third-line r/r aggressive NHL (PIX301) Second-line r/r aggressive NHL (PIX306) First-line aggressive NHL (PIX203) Myelofibrosis (<100,000plts) (1) Primary Myelofibrosis Relapsed Lymphoma First-line or r/r Myelodysplastic Syndrome Elderly high-risk r/r AML (OPAL) Maintenance therapy
Slide 5: Investment Highlights
Investment Highlights Pixuvri Approved in E.U. Pacritinib is a Differentiated JAK2 Inhibitor Leading, Late-Stage Oncology Franchise Tosedostat has Shown Encouraging Data in AML/MDS Significant Upcoming Milestones • Late-stage portfolio focused on blood-related cancers • Deep pipeline with 1 product
Slide 6: Recent Strategic Initiatives
Recent Strategic Initiatives Reduced Projected Monthly Cash Burn from an average of ~$5.5mm to ~$4.5mm Initiation of Pacritinib Phase 3 Trial to Q4 2012 Pixuvri Pre-launch Activities in Support of a September 2012 Launch New Hires with Significant Industry and Operational Expertise Implemented Rever
Slide 7: Executive Management Team
Executive Management Team Officers Position Experience James Bianco, MD Principal Founder, President & Chief Executive Officer, and Director • Chief architect of CTI’s portfolio strategy and has secured more than $1.6bn in operating capital • Previously was an Assistant Member in the clinical resear
Slide 8: Pixuvri
8 Pixuvri
Slide 9: Pixuvri: Addresses an Unmet Need
Pixuvri™: Addresses an Unmet Need Anthracyclines: most active class of chemotherapy • Cornerstone agents for NHL, AML, sarcoma, breast • Cumulative cardiac damage is dose limiting Pixuvri™ • Lacks structural motifs that lead to cardiotoxicity - Significant reduction in biochemical, echo-cardiographi
Slide 10: Pixuvri: Conditional Marketing Authorisation
Pixuvri™: Conditional Marketing Authorisation 3 rd /4 th line aggressive B-cell NHL
Slide 11: Comment
Comment Pocantrone dimaleate versus other chemotherapeutic agents asa single-agent salvage treatment in patients with relapsed or refractory aggressive non-Hodgkin lymphoma: Pixantrone: a new agent for relapsed aggressive lymphomas ‘aphase 3, multicentre, open-label, randomised tral
Slide 12: Pixuvri: First to Market for r/r aggressive B-cell NHL
Pixuvri™: First to Market for r/r aggressive B-cell NHL Pixuvri (n=70) Comparator (n=70) P Value Pixuvri (n=50) Comparator (n=49) P value CR/CRu 20% 5.7% 0.021 ORR 40% 14.3% 0.001 PFS 5.3mos 2.6mos HR=0.60 0.005 OS 10.2mos 7.6mos HR=0.79 0.25 CR/CRu 28% 4.1% 0.002 ORR 48% 12.2% <0.001 PFS 5.7mos 2.8
Slide 13: Pixuvri: EU Commercial Opportunity
Pixuvri™: EU Commercial Opportunity Market research supports potential peak penetration ~8,125 patients/year* Market access (pricing) strategy* • Quantitative benefit over physician choice • CR statistically correlative with OS • EU List Price corridor $29,500 - $35,000 - Allows for potential net ex
Slide 14: Pixuvri: U.S. Regulatory Status
Pixuvri™: U.S. Regulatory Status FDA appeal: Office New Drugs (OND) provided path for resubmission - 2 Independent Radiographic Panel confirmed 1st panels results - Document Interim analysis was not conducted then PIX301 trial would be considered a positive study EU launch and pacritinib acquisition
Slide 15: A highly differentiated JAK2 inhibitor
A highly differentiated JAK2 inhibitor
Slide 16: Pacritinib: Inhibits important activating mutations (JAK2 + FLT3)
Pacritinib: Inhibits 2 important activating mutations (JAK2 + FLT3)
Slide 17: Initial Target Market: MF patients with thrombocytopenia
Initial Target Market: MF patients with thrombocytopenia (platelets <10 0 x1 0 9 ) Table 2: Maximum Restarting Doses for Jakafi After Safety Interruption* Current Platelet Count Maximum Dose When Restarting Jakafi Treatment * Greater than or equal to 125 X 109/L 20 mg twice daily 100 to less than 12
Slide 18: 27% MF Patients Have Severe Thrombocytopenia
27% MF Patients Have Severe Thrombocytopenia JAK1/JAK2 inhibitors (ruxolitinib) associated with treatment emergent thrombocytopenia and anemia Pacritinib: selective JAK2 inhibitor lacks myelosupporession; potentially first to market for MF patients with low platelets ( < 100,000/uL ) Source: MPN Res
Slide 19: Pacritinib: Targets patient population unserved by ruxolitinib
Pacritinib: Targets patient population unserved by ruxolitinib Ruxolitinib approval trials excluded patients <100,00/uL platelets - 93% COMFORT II had normal platelets, median COMFORT I, 244,000/uL - However, MF patients with low platelet counts are higher risk population Ruxolitinib study* (n=41) M
Slide 20: Summary Clinical Trial Results JAK Inhibitors in MF
Summary Clinical Trial Results JAK Inhibitors in MF Company Drug Stage SX Spleen >50% PE Spleen >35% MRI RBC JAK2 V617F* Platelet cutoff Side Effects Pacritinib Demonstrates a Truly Differentiated Side-Effect Profile Pacritinib JAK2-wt JAK2 V617F FLT-3 Phase 3 (Phase 2 n=65)** >50% 42% 32% NR >30% N
Slide 21: Pacritinib: Phase 2 Studies
Pacritinib: Phase 2 Studies Source: ASH 2011.
Slide 22: Pacritinib: Phase 2 Studies (combined)
Pacritinib: Phase 2 Studies (combined) Source: ASH 2011.
Slide 23: Pacritinib: Phase 2 Efficacy (combined)
Pacritinib: Phase 2 Efficacy (combined) 27 of 65 (42%) patients had response of 50% 14 of 65 (21%) had complete response with resolution of splenomegaly 8 of 26 (32%) treated with SB1518 had 35% reduction by MRI* Source: ASH 2011. *Among patients who had MRI measurements (8 patients did not have bas
Slide 24: Pacritinib: Benefit Independent of Platelet Count
Pacritinib: Benefit Independent of Platelet Count Assessment Maximum decrease from baseline Patients with baseline platelet counts 150,000 N=36 All Evaluable Patients N=65 PE 50% 14 (39%) 27 (42%) Source: ASH 2011. * Reduction of splenomegaly was observed with similar frequency in patients with norm
Slide 25: Pacritinib: Minimal Effect on Platelet Counts
Pacritinib: Minimal Effect on Platelet Counts Lack of treatment emergent thrombocytopenia observed in patients with low starting platelet counts Source: Komrokji. R., et al
Slide 26: Pacritinib: Lack of treatment associated anemia
Pacritinib: Lack of treatment associated anemia Source: Komrokji. R., et al
Slide 27: Pacritinib: Durable Improvement in MF Related Symptoms
Pacritinib: Durable Improvement in MF Related Symptoms Source: ASH 2011.
Slide 28: Contemplated Phase 3 Trial Designs
Contemplated Phase 3 Trial Designs Target Indication: • Patients with PMF, PPV-MF, PET-MF with splenomegaly and thrombocytopenia • Two phase 3 trials, each approximately 270 patients - Pacritinib Vs BAT - Pacritinib Vs BAT including patients on low dose ruxolitonib (5,10mg) with treatment emergent t
Slide 29: Pacritinib: Certain Key Deal Terms
Pacritinib: Certain Key Deal Terms Acquired molecule from S*Bio • S*BIO was established as a joint venture between The Singapore Economic Development Board Investments and Chiron Corporation as Singapore’s first fully- integrated, drug discovery company Upfront payment $30mm • $15 million cash • $15
Slide 30: A new class of cancer targeted agents
A new class of cancer targeted agents AADR inducers
Slide 31: Tosedostat: Novel Mechanism of Action AADR Inducer
Tosedostat: Novel Mechanism of Action AADR Inducer Targets members of aminopeptidase family Induces genes characteristic of Amino Acid Deprivation Response (AADR) resulting in cell death AADR changes only seen in transformed (tumor) cells and not normal cells Demonstrated clinical activity across ra
Slide 32: Tosedostat: OPAL Study Results
Tosedostat: OPAL Study Results Encouraging Phase 2 data - r/r elderly AML (n=73) • Oral once-a-day dosing for 6 months • 16 of 50 (32%) evaluable patients had bone marrow response - 9 (12%) of which were complete bone marrow responses • 9 of 25 (36%) patients who previously failed therapy with HMA h
Slide 33: Tosedostat: Phase 2 Study
Tosedostat: Phase 3 Study Data support pivotal trial: high risk MDS/secondary AML Phase 3 trial options: • Relapsed/refractory setting combination with LDAC - High risk heterogenous patient population - Several drugs currently targeting this population • st line setting combination with HMA - Substa
Slide 34: Partnership with Chroma Therapeutics
Partnership with Chroma Therapeutics Exclusive co-development and marketing rights in the Americas • Chroma Therapeutics has ROW rights Cost-sharing • CTI bears 75% of agreed upon direct development expenses • Registration trials aimed at US/EU regulatory approval Initial Payments • $5mm upon execut
Slide 35: Financial Overview
Financial Overview
Slide 36: Financial Overview Capital Structure and Financial Statistics
Financial Overview Capital Structure and Financial Statistics Exchanges / Tickers • NASDAQ: CTIC and MTA: CTIC.MI Market Capitalization • ~$125mm Shares Outstanding • ~56.6mm Cash • $24mm (1) Debt • None Projected Cash Burn • ~$4.5mm / month Cash Remaining • January 2013 Estimated Cash Burn (2) • $5
Slide 37: Expected News Flow
Expected News Flow Upcoming Planned Events • Pixuvri launch in the EU • Pacritinib phase 3 trial initiation in Myelofibrosis • Brostallicin- SABC triple negative breast cancer • OPAXIO interim survival analysis Phase 3 ovarian cancer trial • IQWiG innovation score assignment Upcoming publications •
Cell Therapeutics — Investor Presentation (September 2012) on 6ix